[STRATEGIC] Clinical Trial Technology · Life
Sciences · PE Exit
— Announced Oct 29, 2025 — CLOSED
March 24, 2026
Thermo Fisher Closes $8.875B Acquisition of
Clario, Adding AI-Driven Clinical Trial Endpoint Data to Its Arsenal
The world's leading science services company acquires the
clinical trial endpoint data platform that has underpinned approximately 70% of
all FDA drug approvals over the past decade — paying $8.875B upfront plus up to
$525M in deferred and performance-linked consideration, in a deal that
redefines clinical research data infrastructure.
DEAL SNAPSHOT
|
UPFRONT CASH CONSIDERATION $8.875 Billion |
ANNOUNCED October 29, 2025 |
|
DEFERRED PAYMENT (JAN 2027) $125 Million |
CLOSED March 24, 2026 |
|
EARNOUT (2026–2027 PERFORMANCE) Up to $400 Million |
SELLER CONSORTIUM Astorg + Nordic Capital
(lead) · Novo Holdings · Cinven |
THE PARTIES
|
ACQUIRER Thermo Fisher Scientific
Inc. (NYSE: TMO) Waltham,
MA-based world leader in serving science. CEO Marc Casper. FY2025 revenues
>$40B. Operates across Life Sciences Solutions, Analytical Instruments,
Specialty Diagnostics, and Laboratory Products & Biopharma Services. The
Clario acquisition lands in the Laboratory Products and Biopharma Services
segment. Thermo Fisher serves pharmaceutical and biotech companies,
hospitals, universities, and government agencies globally. |
TARGET (FROM PE CONSORTIUM) Clario Holdings, Inc. Philadelphia,
PA-based leading provider of endpoint data solutions for clinical trials.
~4,000 employees; FY2025 revenues ~$1.25B. Clario integrates endpoint data
from connected devices, clinical sites, and patients across cardiac (ePRO,
cardiac safety), medical imaging, neurological assessment, and wearable data
capture. Platform has supported approximately 70% of FDA drug approvals over
the past decade. EBITDA margin estimated at ~$650M (implied ~13.6x
acquisition multiple). |
DEAL OVERVIEW
Thermo Fisher
agreed to acquire Clario Holdings from a PE consortium led by Astorg and Nordic
Capital, with Novo Holdings and Cinven also as selling shareholders, for $8.875
billion in cash at close. This represents an estimated EBITDA acquisition
multiple of approximately 13.6x — in line with premium clinical research
platform valuations. In addition to the upfront price, Thermo Fisher agreed to
pay $125 million in January 2027 and up to $400 million in earnout payments
contingent on Clario's business performance in 2026 and 2027, bringing total
potential consideration to approximately $9.4 billion.
The transaction
closed on March 24, 2026 — ahead of the originally guided mid-2026 timeline.
Clario is integrated into Thermo Fisher's Laboratory Products and Biopharma
Services segment. Thermo Fisher expects the deal to be immediately accretive to
adjusted operating margins, delivering approximately $175 million in adjusted
operating income contribution by year five.
"Clario's endpoint data solutions represent a critical and
differentiated capability in modern drug development. By integrating its
AI-driven platform into our scientific infrastructure, we create a more
powerful offering for pharma and biotech customers seeking to accelerate their
clinical programs."
— Marc Casper,
Chairman, President & CEO, Thermo Fisher Scientific
THE CLARIO PLATFORM: WHY IT COMMANDS A $9B
PREMIUM
Clinical trial
endpoint data is the lifeblood of drug approvals. Every drug that goes before
the FDA needs objective, auditable endpoint measurements — cardiac safety (QTc
intervals, ECGs), imaging (MRI lesion counts, tumor response), patient-reported
outcomes (ePRO), and wearable sensor data. Clario has built the gold-standard
platform for collecting, cleaning, adjudicating, and submitting this data to
global regulators.
The "70% of
FDA approvals" statistic is not marketing hyperbole — it reflects the fact
that most major pharmaceutical companies use Clario's cardiac safety and
imaging services as their default vendor because switching risk is too high for
regulatory-critical data. This creates powerful retention and pricing power.
Thermo Fisher's goal is to embed Clario's endpoint capabilities into its
CRO-adjacent services and clinical supply chain, creating an end-to-end drug
development platform that reduces sponsor complexity.
ADVISORS
Buy-side
Legal (Thermo Fisher): WilmerHale
(principal deal counsel) + Axinn, Veltrop & Harkrider LLP (regulatory) +
Freshfields (regulatory)
Sell-side
Financial (Clario / PE consortium): Evercore
(lead financial advisor)
Sell-side
Legal (Clario): Latham & Watkins
LLP